Delcath Systems Incorporated operates in the Surgical and medical instruments sector. Delcath Systems, Inc. (Delcath) is a development-stage, specialty pharmaceutical and medical device company focused on oncology. The Company focuses on the development and clinical study of the Delcath chemosaturation system. It focuses on cancers in the liver. As of December 31, 2010, the Delcath chemosaturation system is designed to deliver high doses of melphalan hydrochloride, or melphalan, directly to the liver while limiting the systemic exposure of this agent. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ. Once the organ is isolated, the chemosaturation system delivers high doses of anti-cancer agents directly to the liver, while limiting systemic exposure and the related side effects by filtering the blood prior to returning it to the patient.